美国 · SEC FORM 4
Inhibrx Biosciences, Inc.
INBX · Nasdaq · CIK 0002007919 · Healthcare · Biotechnology
内部人信号
3 位买方 · 19 条买入交易行 · $6.3M 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
- ⚠ 角色得分低 · 买入者中职位最高的是：Chief Executive Officer（CEO、董事长和持股 10% 以上的股东得分最低）
- ✓ Recent activity · latest purchase 2026-10-14
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Chief Executive Officer, Director. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 73.2
- 73.1
- 75.5
- 75.4
- 75.0
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -14.2%
- 3M
- +6.8%
- 6M
- +1.8%
- 12M
- +149.9%
波动率与流动性
- 波动率
- 99.9%
- Beta
- 3.67
- 平均每日成交额
- USD 27.6M
估值
- 市值
- USD 1.3B
- P/E
- —
基本面
- 利润率
- 0.0%
- ROE
- -1752.2%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-18 · 价格来源：OpenBB/yfinance · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-07 · 来自 Yahoo Finance：利润率 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 3,432,642
- 上期报告
- 3,393,511
- 日均成交量
- 290,359
- 回补天数
- 11.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Lappe Mark | 买入 (P) | Common Stock | 9,940 | USD 84.55 | USD 840,401 | SEC 申报 ↗ |
| 2026-09-28 | Lappe Mark | 买入 (P) | Common Stock | 4,500 | USD 100.76 | USD 453,420 | SEC 申报 ↗ |
| 2026-09-25 | Lappe Mark | 买入 (P) | Common Stock | 5,500 | USD 99.16 | USD 545,373 | SEC 申报 ↗ |
| 2026-09-23 | Kayyem Jon Faiz | 买入 (P) | Common Stock | 5,000 | USD 100.00 | USD 500,000 | SEC 申报 ↗ |
| 2026-09-16 | Kayyem Jon Faiz | 买入 (P) | Common Stock | 5,000 | USD 100.00 | USD 500,000 | SEC 申报 ↗ |
| 2026-09-08 | Lappe Mark | 买入 (P) | Common Stock | 25,000 | USD 105.81 | USD 2,645,358 | SEC 申报 ↗ |
| 2026-09-08 | Kayyem Jon Faiz | 买入 (P) | Common Stock | 5,000 | USD 113.52 | USD 567,600 | SEC 申报 ↗ |
| 2026-09-08 | FORSYTH DOUGLAS | 买入 (P) | Common Stock | 2,500 | USD 114.65 | USD 286,625 | SEC 申报 ↗ |
| 2024-11-20 | Kayyem Jon Faiz | 买入 (P) | Common Stock | 18,750 | USD 14.19 | USD 266,062 | SEC 申报 ↗ |
| 2024-11-19 | Kayyem Jon Faiz | 买入 (P) | Common Stock | 34,843 | USD 14.23 | USD 495,816 | SEC 申报 ↗ |
| 2024-10-03 | Vuori Kristiina MD | 买入 (P) | Common Stock | 6,667 | USD 15.00 | USD 100,005 | SEC 申报 ↗ |
| 2024-09-16 | Lappe Mark | 买入 (P) | Common Stock | 13,037 | USD 17.13 | USD 223,324 | SEC 申报 ↗ |
| 2024-09-12 | Lappe Mark | 买入 (P) | Common Stock | 26,963 | USD 15.05 | USD 405,793 | SEC 申报 ↗ |
| 2024-09-11 | Vuori Kristiina MD | 买入 (P) | Common Stock | 6,457 | USD 15.07 | USD 97,307 | SEC 申报 ↗ |
| 2024-09-10 | Vuori Kristiina MD | 买入 (P) | Common Stock | 179 | USD 15.00 | USD 2,685 | SEC 申报 ↗ |
Form 4 申报证据
24 transaction lines in the latest 365-day window; 69 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Lappe Mark | 买入 (P) | Common Stock | 9,940 | USD 84.55 | USD 840,401 | SEC 申报 ↗ |
| 2026-09-28 | Lappe Mark | 买入 (P) | Common Stock | 4,500 | USD 100.76 | USD 453,420 | SEC 申报 ↗ |
| 2026-09-25 | Lappe Mark | 买入 (P) | Common Stock | 5,500 | USD 99.16 | USD 545,373 | SEC 申报 ↗ |
展开近期 Form 4 证据 (13 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Lappe Mark | 买入 (P) | Common Stock | 9,940 | USD 84.55 | USD 840,401 | SEC 申报 ↗ |
| 2026-09-28 | Lappe Mark | 买入 (P) | Common Stock | 4,500 | USD 100.76 | USD 453,420 | SEC 申报 ↗ |
| 2026-09-25 | Lappe Mark | 买入 (P) | Common Stock | 5,500 | USD 99.16 | USD 545,373 | SEC 申报 ↗ |
| 2026-09-23 | Kayyem Jon Faiz | 买入 (P) | Common Stock | 5,000 | USD 100.00 | USD 500,000 | SEC 申报 ↗ |
| 2026-09-16 | Kayyem Jon Faiz | 买入 (P) | Common Stock | 5,000 | USD 100.00 | USD 500,000 | SEC 申报 ↗ |
| 2026-09-15 | MANHARD KIMBERLY | 卖出 (S) | Common Stock | 500 | USD 105.05 | USD 52,525 | SEC 申报 ↗ |
| 2026-09-14 | MANHARD KIMBERLY | 卖出 (S) | Common Stock | 500 | USD 110.26 | USD 55,130 | SEC 申报 ↗ |
| 2026-09-11 | MANHARD KIMBERLY | 卖出 (S) | Common Stock | 500 | USD 111.78 | USD 55,890 | SEC 申报 ↗ |
| 2026-09-09 | MANHARD KIMBERLY | 卖出 (S) | Common Stock | 500 | USD 115.80 | USD 57,900 | SEC 申报 ↗ |
| 2026-09-08 | MANHARD KIMBERLY | 卖出 (S) | Common Stock | 500 | USD 115.14 | USD 57,570 | SEC 申报 ↗ |
| 2026-09-08 | Lappe Mark | 买入 (P) | Common Stock | 25,000 | USD 105.81 | USD 2,645,358 | SEC 申报 ↗ |
| 2026-09-08 | Kayyem Jon Faiz | 买入 (P) | Common Stock | 5,000 | USD 113.52 | USD 567,600 | SEC 申报 ↗ |
| 2026-09-08 | FORSYTH DOUGLAS | 买入 (P) | Common Stock | 2,500 | USD 114.65 | USD 286,625 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | INBX |
| CIK | 0002007919 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 69 transaction lines from 2024-05-29 to 2026-10-14 46 P purchase lines · 8 S sale lines · 15 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.